Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Drug Profile

Influenza virus vaccine quadrivalent - Protein Sciences Corporation

Alternative Names: FluBlok Quadrivalent; FluBlok-Q; Quadrivalent recombinant influenza vaccine seasonal – Protein Sciences Corporation; RIV4; Seasonal quadrivalent influenza vaccine – Protein Sciences Corporation

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Protein Sciences Corporation
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza virus infections

Most Recent Events

  • 18 Oct 2016 Protein Sciences Corporation completes a phase III trial in Influenza virus infections (Prevention, In adults, In volunteers) in USA (NCT02285998)
  • 11 Oct 2016 Registered for Influenza virus infections (In adolescents, In children, In adults, Prevention) in USA - First global approval (IM)
  • 27 Jun 2016 Preregistration for Influenza virus infections (Prevention, In adults, In children, In adolescents) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top